No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Guangdong Jiaying Pharmaceutical (002198.SZ): has repurchased a total of 1.416% of shares.
On February 6, Gelonghui reported that Guangdong Jiaying Pharmaceutical (002198.SZ) announced that as of January 31, 2025, the company had repurchased a total of 7,187,100 shares through a designated Share Buyback securities account via centralized bidding, accounting for 1.4161% of the company's current total share capital. The highest Fill Price for the buyback was 7.04 yuan per share, the lowest Fill Price was 6.78 yuan per share, and the total amount of the buyback was 49.46925 million yuan (excluding transaction fees).
The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.
① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.
Guangdong Jiaying Pharmaceutical (002198.SZ): Share buyback has not yet been implemented.
Gelonghui, January 2nd丨Guangdong Jiaying Pharmaceutical (002198.SZ) announced that as of December 31, 2024, the company has not implemented a share buyback.
Jiaying Pharmaceutical to Buy Back Up to 132 Million Yuan of Shares
Guangdong Jiaying Pharmaceutical (002198.SZ): Plans to launch the 2024 employee stock ownership plan with a total fundraising amount not exceeding 60.615 million yuan.
On December 13, Gelonghui announced that Guangdong Jiaying Pharmaceutical (002198.SZ) has released a draft for the 2024 employee stock ownership plan. This plan aims to raise a total of no more than 60.615 million yuan, with each unit valued at 1 yuan, reserving 11.8536 million units. The upper limit for the number of units in this employee stock ownership plan is 60.615 million units, and the final total amount raised will be based on the actual fundraising total. The stocks for this employee stock ownership plan are sourced from the company's repurchase of Guangdong Jiaying Pharmaceutical A-share common stocks from the secondary market, and the number of stocks intended to be held in this plan is not specified.
Guangdong Jiaying Pharmaceutical (SZSE:002198) Delivers Shareholders Favorable 9.6% CAGR Over 3 Years, Surging 16% in the Last Week Alone
